Prognostic significance of phosphorylated 4E-binding protein 1 in non-small cell lung cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 4, 2015, Pages 3955-3962

  Lee, Hyoun Wook ^a   Lee, Eun Hee ^a   Lee, Ji Hyun ^a   Kim, Jeong Eun ^a   Kim, Seok Hyun ^a   Kim, Tae Gyu ^a   Hwang, Sang Won ^a   Kang, Kyung Woo ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Immunohistochemistry; Non small cell lung cancer; p 4E BP1; Prognosis

Indexed keywords

EIF4EBP1 PROTEIN, HUMAN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADULT; AGED; FEMALE; HUMAN; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; SURVIVAL RATE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPROTEINS; PHOSPHORYLATION; PROGNOSIS; SURVIVAL RATE;

EID: 84936096995     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Parkin DM. Gloal cancer statistics in the year 2000. Lancet Oncol 2001; 55: 371-377.
2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Eng J Med 2004; 59: 225-249.
3. Mok TS, Zhou Q, Leung L, Loong HH. Personalized medicine for non-small-cell lung cancer. Expert Rev Anticancer Ther 2010; 10: 1601-1611.
4. Burris HA 3rd. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 2013; 71: 829-842.
5. Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol 2012; 7: 1315-1326.
6. Armengol G, Rojo F, Castellví J, Iglesias C, Cuatrecasas M, Pons B, Baselga J, Ramón y Cajal S. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 2007; 67: 7551-7555.
7. Averous J, Proud CG. When translation meets transformation: the mTOR story. Oncogene 2006; 25: 6423-6435.
8. Yeh CJ, Chuang WY, Chao YK, Liu YH, Chang YS, Kuo SY, Tseng CK, Chang HK, Hsueh C. High expression of phosphorylated 4E-binding protein 1 is an adverse prognostic factor in esophageal squamous cell carcinoma. Virchows Arch 2011; 458: 171-178.
9. Korkolopoulou P, Levidou G, El-Habr EA, Piperi C, Adamopoulos C, Samaras V, Boviatsis E, Thymara I, Trigka EA, Sakellariou S, Kavantzas N, Patsouris E, Saetta AA. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas. Histopathology 2012; 61: 293-305.
10. Castellvi J, Garcia A, Ruiz-Marcellan C, Hernández-Losa J, Peg V, Salcedo M, Gil-Moreno A, Ramon y Cajal S. Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis. Hum Pathol 2009; 40: 1418-1426.
11. O'Reilly KE, Warycha M, Davies MA, Rodrik V, Zhou XK, Yee H, Polsky D, Pavlick AC, Rosen N, Bhardwaj N, Mills G, Osman I. Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res 2009; 15: 2872-2878.
12. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, Ramon y Cajal S. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006; 107: 1801-1811.
13. Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, Sonenberg N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 1999; 13: 1422-1437.
14. Ayuso MI, Hernández-Jiménez M, Martín ME, Salinas M, Alcázar A. New hierarchical phosphorylation pathway of the translational repressor eIF4E-binding protein 1 (4E-BP1) in ischemia-reperfusion stress. J Biol Chem 2010; 285: 34355-34363.
15. Tsim S, O'Dowd CA, Milroy R, Davidson S. Staging of non-small cell lung cancer (NSCLC): a review. Respir Med 2010; 104: 1767-1774.
16. Seki N, Takasu T, Sawada S, Nakata M, Nishimura R, Segawa Y, Shibakuki R, Hanafusa T, Eguchi K. Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma. Lung Cancer 2010; 70: 329-334.
17. Trigka EA, Levidou G, Saetta AA, Chatziandreou I, Tomos P, Thalassinos N, Anastasiou N, Spartalis E, Kavantzas N, Patsouris E, Korkolopoulou P. A detailed immunohistochemical anaylsis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Oncol Rep 2013; 30: 623-636.
18. Nishi T, Iwasaki K, Ohashi N, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kobayashi T, Kodera Y. Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells. Cancer Lett 2013; 331: 220-229.